Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 8, 2015, Pages 1513-1520.e1

  Arulanandan, Ahilan ^a   Ang, Brandon ^a   Bettencourt, Ricki ^a   Hooker, Jonathan ^a   Behling, Cynthia ^a   Lin, Grace Y ^a   Valasek, Mark A ^a   Ix, Joachim H ^a   Schnabl, Bernd ^a   Sirlin, Claude B ^a   Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular Disease; Cardiovascular Risk; Detection; Heart and Vascular Disease; Liver Fat; Magnetic Resonance Imaging; Nonalcoholic Steatohepatitis; Noninvasive; Noninvasive Biomarker; Prognostic Factor

Indexed keywords

FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY FAT; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FAT CONTENT; FEMALE; HUMAN; HUMAN TISSUE; LIVER FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON DENSITY FAT FRACTION; AGED; CALIFORNIA; COMPLICATION; LIVER; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT;

ADULT; AGED; CALIFORNIA; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK ASSESSMENT;

EID: 84937522314     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.01.027     Document Type: Article

References (41)

1. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
2. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
3. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2014, Epub ahead of print.
4. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
5. Vodkin I., Valasek M.A., Bettencourt R., et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015, 41:368-378.
6. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
7. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
8. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
9. Loomba R., Hwang S.J., O'Donnell C.J., et al. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008, 134:953-959.
10. VanWagner L.B., Ning H., Lewis C.E., et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis 2014, 235:599-605.
11. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. NEngl J Med 2010, 363:1341-1350.
12. Pickhardt P.J., Hahn L., Muñoz del Rio A., et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol 2014, 202:752-758.
13. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. JHepatol 2008, 49:608-612.
14. Söderberg C., Stål P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
15. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
16. Noureddin M., Lam J., Peterson M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58:1930-1940.
17. Loomba R., Wolfson T., Ang B., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014, 60:1920-1928.
18. Le T.A., Chen J., Changchien C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932.
19. Tang A., Tan J., Sun M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013, 267:422-431.
20. Johnson B.L., Schroeder M.E., Wolfson T., et al. Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. JMagn Reson Imaging 2014, 39:440-447.
21. Hines C.D., Frydrychowicz A., Hamilton G., et al. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. JMagn Reson Imaging 2011, 33:873-881.
22. Meisamy S., Hines C.D., Hamilton G., et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011, 258:767-775.
23. Loomba R., Sirlin C.B., Ang B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology 2014, Epub ahead of print.
24. Patel N.S., Doycheva I., Peterson M.R., et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015, 13:561-568.
25. Permutt Z., Le T.A., Peterson M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012, 36:22-29.
26. Tang A., Desai A., Hamilton G., et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015, 274:416-425.
27. Patel N.S., Peterson M.R., Brenner D.A., et al. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 37:630-639.
28. Yokoo T., Bydder M., Hamilton G., et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009, 251:67-76.
29. Yokoo T., Shiehmorteza M., Hamilton G., et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 2011, 258:749-759.
30. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection Ea, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
31. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
32. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
33. Reeder S.B., Hu H.H., Sirlin C.B. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. JMagn Reson Imaging 2012, 36:1011-1014.
34. Yu H., Shimakawa A., Hines C.D., et al. Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med 2011, 66:199-206.
35. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
36. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
37. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
38. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
39. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. JAm Coll Cardiol 2010, 56:1113-1132.
40. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
41. St George A., Bauman A., Johnston A., et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50:68-76.